Tocilizumab and other targeted therapies for severe cutaneous immune-related adverse events. Thompson LL, Chen ST. Br J Dermatol 2020 Sep 6. doi: 10.1111/bjd.19322.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Thompson LL, Chen ST. Tocilizumab and other targeted therapies for severe cutaneous immune-related adverse events. Br J Dermatol 2020 Sep 6. doi: 10.1111/bjd.19322.
PMID: 32892364